Year archive

Jacobio Pharmaceuticals Group Co., Ltd. — 2024 filings

All 63 regulatory filings released by Jacobio Pharmaceuticals Group Co., Ltd. (1167) in 2024, sourced directly from the official regulator.

63 Filings

2024 Period

2024 filings (63)

Filing	Released	Lang
VOLUNTARY ANNOUNCEMENT JACOBIO PRESENTED THE PRELIMINARY CLINICAL DATA OF BET INHIBITOR JAB-8263 TO TREAT MYELOFIBROSIS AT THE 2024 66TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING Regulatory Filings	2024-12-09	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 November 2024 Regulatory Filings	2024-12-03	English
VOLUNTARY ANNOUNCEMENT JACOBIO COMPLETED FIRST PATIENT DOSAGE IN THE PHASE I/IIa CLINICAL TRIAL OF PAN-KRAS INHIBITOR JAB-23E73 IN CHINA Regulatory Filings	2024-11-25	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2024 Regulatory Filings	2024-11-04	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2024-10-25	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2024-10-21	English
VOLUNTARY ANNOUNCEMENT GLECIRASIB FOR THE TREATMENT OF PANCREATIC CANCER HAS BEEN GRANTED ORPHAN DRUG DESIGNATION IN EUROPE Regulatory Filings	2024-10-21	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2024-10-18	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2024-10-09	English
VOLUNTARY ANNOUNCEMENT JACOBIO PRESENTED THE PRE-CLINICAL DATA OF SHP2 INHIBITOR JAB-3312 IN COMBINATION WITH KRAS G12C INHIBITOR GLECIRASIB AT THE FIFTH RAS INITIATIVE SYMPOSIUM 2024 Regulatory Filings	2024-10-09	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2024-10-08	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2024 Regulatory Filings	2024-10-07	English
VOLUNTARY ANNOUNCEMENT JACOBIO TO PRESENT THE CLINICAL DATA OF BET INHIBITOR JAB-8263 AT THE 2024 66TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING Regulatory Filings	2024-10-03	English
2024 INTERIM REPORT Interim / Quarterly Report	2024-09-27	English
VOLUNTARY ANNOUNCEMENT JACOBIO RECEIVED UPFRONT PAYMENT UPON THE ENTRY INTO EXCLUSIVE LICENSING-OUT AGREEMENT FOR GLECIRASIB AND JAB- 3312 WITH ALLIST Capital/Financing Update	2024-09-27	English
VOLUNTARY ANNOUNCEMENT JACOBIO RECEIVED CHINA CDE INVESTIGATIONAL NEW DRUG CLEARANCE FOR PAN-KRAS INHIBITOR JAB-23E73 Regulatory Filings	2024-09-26	English
VOLUNTARY ANNOUNCEMENT JACOBIO RECEIVED INVESTIGATIONAL NEW DRUG (IND) APPROVAL FROM THE U.S. FDA FOR PAN-KRAS INHIBITOR JAB-23E73 Regulatory Filings	2024-09-23	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 August 2024 Regulatory Filings	2024-09-03	English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS Board/Management Information	2024-08-30	English
(1) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024; (2) RESIGNATION OF NON-EXECUTIVE DIRECTOR; AND (3) CHANGE IN THE COMPOSITION OF THE REMUNERATION COMMITTEE AND THE NO Interim / Quarterly Report	2024-08-30	English
INSIDE INFORMATION - JACOBIO ANNOUNCES EXCLUSIVE LICENSING-OUT AGREEMENT WITH ALLIST FOR GLECIRASIB AND JAB-3312 Capital/Financing Update	2024-08-30	English
SUPPLEMENTAL ANNOUNCEMENT TO THE 2023 INTERIM REPORT AND THE 2023 ANNUAL REPORT Capital/Financing Update	2024-08-21	English
DATE OF BOARD MEETING Regulatory Filings	2024-08-20	English
VOLUNTARY ANNOUNCEMENT JACOBIO COMPLETED FIRST PATIENT DOSAGE IN THE PHASE III CLINICAL TRIAL OF JAB-3312 IN COMBINATION WITH GLECIRASIB Regulatory Filings	2024-08-07	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 July 2024 Major Shareholding Notification	2024-08-01	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 June 2024 Transaction in Own Shares	2024-07-03	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2024-06-27	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2024-06-26	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2024-06-25	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2024-06-24	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2024-06-21	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2024-06-20	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2024-06-19	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2024-06-18	English
NEXT DAY DISCLOSURE RETURN Share Issue/Capital Change	2024-06-17	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2024-06-14	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2024-06-13	English
VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE Transaction in Own Shares	2024-06-11	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 7, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-06-07	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May 2024 Regulatory Filings	2024-06-03	English
VOLUNTARY ANNOUNCEMENT JACOBIO PRESENTED TWO CLINICAL DATA AT THE 2024 ASCO Regulatory Filings	2024-06-02	English
VOLUNTARY ANNOUNCEMENT THE NMPA OF CHINA HAS ACCEPTED AND GRANTED PRIORITY REVIEW DESIGNATION TO THE NDA FOR GLECIRASIB Regulatory Filings	2024-05-21	English
VOLUNTARY ANNOUNCEMENT CHINA CDE CLEARANCE FOR PHASE III CLINICAL TRIAL OF KRAS G12C INHIBITOR GLECIRASIB IN COMBINATION WITH CETUXIMAB IN PATIENTS WITH COLORECTAL CANCER Regulatory Filings	2024-05-10	English
VOLUNTARY ANNOUNCEMENT SUBMISSION OF NEW DRUG APPLICATION FOR KRAS G12C INHIBITOR GLECIRASIB Regulatory Filings	2024-05-06	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2024 Regulatory Filings	2024-05-06	English
FORM OF PROXY FOR THE 2024 ANNUAL GENERAL MEETING Proxy Solicitation & Information Statement	2024-04-26	English
NOTICE OF 2024 ANNUAL GENERAL MEETING AGM Information	2024-04-26	English
PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, PROPOSED RE-ELECTION OF DIRECTORS, PROPOSED CHANGE OF AUDITOR AND NOTICE OF ANNUAL GENERAL MEETING Proxy Solicitation & Information Statement	2024-04-26	English
PROPOSED CHANGE OF AUDITOR Audit Report / Information	2024-04-24	English
2023 ANNUAL REPORT Annual Report	2024-04-24	English
VOLUNTARY ANNOUNCEMENT JACOBIO PRESENT ED CLINICAL DATA OF PARP7 INHIBITOR JAB-26766 AND P53 REACTIVATOR JAB-30355 AT THE AACR 2024 Regulatory Filings	2024-04-09	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2024 Regulatory Filings	2024-04-03	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 Annual Report	2024-03-28	English
DATE OF BOARD MEETING Report Publication Announcement	2024-03-18	English
VOLUNTARY ANNOUNCEMENT Regulatory Filings	2024-03-05	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 29 February 2024 Share Issue/Capital Change	2024-03-04	English
Notification Letter and Reply Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications Regulatory Filings	2024-03-01	English
Notification Letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications Report Publication Announcement	2024-03-01	English
VOLUNTARY ANNOUNCEMENT JACOBIO RECEIVED US FDA INVESTIGATIONAL NEW DRUG CLEARANCE FOR P53 Y220C Activator JAB-30300 Regulatory Filings	2024-03-01	English
VOLUNTARY ANNOUNCEMENT THE REGISTRATIONAL PHASE III CLINICAL TRIAL OF SHP2 INHIBITOR JAB-3312 IN COMBINATION WITH KRAS G12C INHIBITOR GLECIRASIB APPROVED BY THE CENTER FOR DRUG EVALUATION (CDE) OF THE Regulatory Filings	2024-02-18	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 January 2024 Regulatory Filings	2024-02-05	English
VOLUNTARY ANNOUNCEMENT JACOBIO PRESENTED CLINICAL DATA OF KRAS G12C INHIBITOR GLECIRASIB IN PATIENTS WITH PANCREATIC CANCER AND OTHER SOLID TUMORS AT THE 2024 ASCO GI Regulatory Filings	2024-01-21	English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 December 2023 Regulatory Filings	2024-01-04	English